{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+Control&page=46",
    "query": {
      "intervention": "Carbohydrate Control",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 1871,
    "total_pages": 188,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+Control&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+Control&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-30T07:08:33.386Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02093221",
      "title": "Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "180 mg/kg Alpha1-PI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "90 mg/kg Alpha1-PI",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Grifols Therapeutics LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "6 Years to 35 Years"
      },
      "enrollment_count": 76,
      "start_date": "2014-03",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2018-09-05",
      "last_synced_at": "2026-10-30T07:08:33.386Z",
      "location_count": 36,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Orange, California + 28 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02093221"
    },
    {
      "nct_id": "NCT00998738",
      "title": "Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuropathy",
        "Pain",
        "Recurrent Breast Carcinoma",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Calcium Gluconate",
          "type": "DRUG"
        },
        {
          "name": "Magnesium Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2009-11",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2016-02-04",
      "last_synced_at": "2026-10-30T07:08:33.386Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00998738"
    },
    {
      "nct_id": "NCT07797335",
      "title": "AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Cardiovascular Risk"
      ],
      "interventions": [
        {
          "name": "Zenagamtide",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine U-100",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 1778,
      "start_date": "2026-08-24",
      "completion_date": "2028-09-20",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-30T07:08:33.386Z",
      "location_count": 109,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Montgomery, Alabama + 91 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07797335"
    },
    {
      "nct_id": "NCT05175248",
      "title": "Nutritional Intervention for Endometriosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Endometriosis"
      ],
      "interventions": [
        {
          "name": "Plant-based Intervention Group",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Physicians Committee for Responsible Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2022-03-02",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-30T07:08:33.386Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05175248"
    },
    {
      "nct_id": "NCT04000555",
      "title": "Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Clostridium Difficile Infection",
        "Clostridium Difficile Infection Recurrence"
      ],
      "interventions": [
        {
          "name": "Oral Vancomycin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of South Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2019-09-01",
      "completion_date": "2022-06-11",
      "has_results": false,
      "last_update_posted_date": "2023-04-21",
      "last_synced_at": "2026-10-30T07:08:33.386Z",
      "location_count": 2,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04000555"
    },
    {
      "nct_id": "NCT00244478",
      "title": "Soy, Bone and Health in College Females",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoporosis",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Soy Protein Dietary Supplement",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Georgia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "19 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 19 Years · Female only"
      },
      "enrollment_count": 120,
      "start_date": "2005-10",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2015-09-25",
      "last_synced_at": "2026-10-30T07:08:33.386Z",
      "location_count": 1,
      "location_summary": "Athens, Georgia",
      "locations": [
        {
          "city": "Athens",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244478"
    },
    {
      "nct_id": "NCT05285878",
      "title": "Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Fibrosis",
        "Kidney Transplant; Complications",
        "Kidney Transplant Rejection",
        "Kidney Transplant Failure and Rejection",
        "Kidney Transplant Failure",
        "Kidney Failure, Chronic",
        "Graft Rejection"
      ],
      "interventions": [
        {
          "name": "Fingolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Methodist Hospital Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2022-07-28",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-10-30T07:08:33.386Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05285878"
    },
    {
      "nct_id": "NCT04624204",
      "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab 200 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab 400 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab placebo (saline)",
          "type": "DRUG"
        },
        {
          "name": "Olaparib 300 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Olaparib matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Etoposide 100 mg/m^2",
          "type": "DRUG"
        },
        {
          "name": "Platinum, investigator's choice",
          "type": "DRUG"
        },
        {
          "name": "Standard Thoracic Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Prophylactic Cranial Irradiation (PCI)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 672,
      "start_date": "2020-12-08",
      "completion_date": "2027-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-30T07:08:33.386Z",
      "location_count": 35,
      "location_summary": "Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04624204"
    },
    {
      "nct_id": "NCT01111149",
      "title": "Varenicline and Smoking Cessation in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia",
        "Smoking Cessation"
      ],
      "interventions": [
        {
          "name": "Sugar Pill",
          "type": "OTHER"
        },
        {
          "name": "Varenicline",
          "type": "DRUG"
        },
        {
          "name": "Bupropion HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2009-12",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-07-17",
      "last_synced_at": "2026-10-30T07:08:33.386Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01111149"
    },
    {
      "nct_id": "NCT06068543",
      "title": "Reducing Frailty for Older Cancer Survivors Using Supplements II",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Frailty",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Epigallocatechin-3-Gallate (EGCG)",
          "type": "DRUG"
        },
        {
          "name": "Microcrystalline cellulose (MCC)",
          "type": "DRUG"
        },
        {
          "name": "Ascorbic Acid (Vitamin C)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 118,
      "start_date": "2024-10-25",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-10-30T07:08:33.386Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06068543"
    }
  ]
}